Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences

Published on :

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be hosting an R&D Day Event and participating in upcoming scientific conferences. Please see additional details below:

Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

Orgenesis Logo
Published on :

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and The Johns Hopkins University, today announce the next phase of their collaboration. This new phase involves construction of a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in Q2 2022 and is expected to be operational in Q2 of 2023.

TEDCO 2021 Recap – Successful Initiatives and New Funding Programs

TEDCO logo over a backdrop of the Maryland flag
Published on :

2021 was a phenomenal year for TEDCO (Maryland Technology Development Corporation)! Despite challenges and setbacks due to COVID-19, the venture and equity investment organization pushed boundaries and made phenomenal strides in growth and expansion across the state of Maryland. TEDCO also provided crucial funding, resources, and networking opportunities for entrepreneurs and startups in the state.

Avidea Merger with Vaccitech Provides New Opportunities for SNAPvax Platform

Image with the Avidea and Vaccitech logos with an image of Avidea's SNAPvax technology
Published on :

Privately-held Avidea is developing next-generation T cell immunotherapies for the treatment of cancer and autoimmune diseases. The company’s immunotherapies are driven by its polymer-drug conjugate technology platform, SNAPvax, which is designed to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition. This is done so in order to enable the development of immunotherapy product candidates with tighter control over immune responses. The SNAPvax platform is designed to induce high magnitude cytotoxic T cells for treating cancer and chronic infections. It can also be configured to induce regulatory T cells for treating autoimmunity and allergies.

Institute for Bioscience and Biotechnology Research Receives $16.8 M Investment from the National Institute of Standards and Technology

IBBR Logo
Published on :

The Institute for Bioscience and Biotechnology Research (IBBR) announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology (NIST) headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino (NIST). This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments for addressing other crucial health challenges.

McBee, Moore & Vanik IP: Intellectual Property Law Firm Celebrates Six Years

Published on :

McBee, Moore & Vanik IP, LLC began in 2016 when partners Susan McBee, C.G. Moore, David Vanik and 12 employees came together to form a new patent law firm with improved client service as the ultimate goal. This year, the firm is celebrating six years together. 

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax’ COVID-19 Vaccine in South Africa

Novavax logo
Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced a regulatory submission to the South African Health Products Regulatory Agency (SAHPRA) for emergency use authorization (EUA) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. If authorized, the vaccine (known as NVX-CoV2373) will be manufactured by and commercialized by SII in South Africa under the brand name Covovax™.

Infectious Disease Focused Zalgen Labs Opens New HQ in Frederick, Eyes Clinical Trial for Lassa Fever Therapeutic

Zalgen logo overlaying a photo of three laboratory workers in PPE
Published on :

Zalgen Labs, which until late December been housed at the Germantown Innovation Center for the past eight years, is focused on developing diagnostics and therapeutics for infectious emerging viral threats that have become endemic in the far corners of the world, including diseases such as Lassa fever, Ebola and other hemorrhagic diseases.

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn’s Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Avalo Therapeutics logo
Published on :

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases, today provides a comprehensive update on the Company’s growth opportunities and mid-stage development portfolio.